Surgery of residual masses after chemotherapy in patients with testicular cancer;Chirurgie des masses résiduelles après chimiothérapie du cancer du testicule

Revue du Praticien

Volumn 57, Issue 4, 2007, Pages 389-398

  Fléchon, Aude ^a   Rivoire, Michel ^a   Berger, Nicole ^b  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; FOLLOW UP; HUMAN; LUNG METASTASIS; MEDIASTINUM LYMPH NODE; ORCHIECTOMY; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SEMINOMA; TESTIS CANCER;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM, RESIDUAL; NEOPLASMS, GERM CELL AND EMBRYONAL; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RETROPERITONEAL SPACE; SEMINOMA; TERATOMA; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947516452     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumours with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40.
2. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.J Clin Oncol 1997;15:594-603.
3. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer.J Urol 1982;128:315-20.
4. Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8:1683-94.
5. Donohue JP. Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol Oncol 2003;21:129-32.
6. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13:1177-87.
7. Vergouwe Y, Steyerberg EW, de Wit R, et al. External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer 2003;88:843-7.
8. Stephens AW, Gonin R, Hutchins GD, et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996;14:1637-41.
9. Steyerberg EW, Marshall PB, Keizer HJ, et al. Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: a decision analysis. Cancer 1999;85:1331-41.
10. Donohue JP. Metastatic pathways of nonseminomatous germ cell tumors. Semin Urol 1984;2:217-29.
11. Wood DP Jr, Herr HW, Heller G, et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 1992;148:1812-5.
12. Aprikian AG, Herr HW, Bajorin DF, et al. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 1994;74:1329-34.
13. Baniel J, Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol 1999;17:263-7.
14. Motzer R, Bosl G, Heelan R, et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987;5:1064-70.
15. Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997;157:860-2.
16. Ravi R, Ong J, Oliver RT, Badenoch DF, Fowler CG, Hendry WF. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 1999;83:649-53.
17. Fossa SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaaihus O. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 1987;5:1071-7.
18. Fossa SD, Droz JP, Stoter G, Kaye SB, Vermeylen K, Sylvester R. Cisplatin, vincristine and ifosfamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br J Cancer 1995;71:619-24.
19. Horwich A, Dearnaley DP, Duchesne GM, Williams M, Brada M, Peckham MJ. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 1989;7:1150-6.
20. Donohue JP, Foster RS. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am 1998;25:461-8.
21. Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1996;14:454-60.
22. Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002;168:1975-9.
23. Culine S, Abs L, Terrier-Lacombe MJ, Theodore C, Wibault T, Droz JP. Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience. Eur J Cancer 1998;34:353-8.
24. Peckham MJ, Horwich A, Hendry WF. Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 1985;52:7-13.
25. Wilkinson PM, Read G, Magee B. The treatment of advanced seminoma with chemotherapy and radiotherapy. Br J Cancer 1988;57:100-4.
26. Horwich A, Paluchowska B, Norman A, et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997;8:37-40.
27. Duchesne GM, Senning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997;33:829-35.
28. Loehrer PJ, Birch R, Williams SD, Greco FA, Einhorn LH. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987;5:1212-20.
29. Amato RJ, Ellerhorst J, Banks M, Logothetis CJ. Carboplatin and ifosfamide and selective consolidation in advanced seminoma. Eur J Cancer 1995;31A:2223-8.
30. Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993;11:1703-9.
31. Bachaud JM, Berthier F, Soulie M, et al. Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma. Radiother Oncol 1999;50:191-7.
32. Fossa SD, Langmark F, Aass N, Andersen A, Lothe R, Borresen AL. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer 1990;61:639-43.
33. Schultz SM, Einhorn LH, Conces DJ, Williams SD, Loehrer PJ. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989;7:1497-503.
34. Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999;17:3457-60.
35. de Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740-4.
36. de Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D- glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034-9.
37. Schmoll HJ, Souchon R, Krege S, et al. European Germ Cell Cancer Consensus Group. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-99.
38. th edition Philadelphie: Lippincott Williams and Willeins 1999: 1983-6.
39. Steyerberg EW, Keizer HJ, Messemer JE, et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group. Cancer 1997;79:345-55.
40. Albers P, Weissbach L, Krege S, et al. German Testicular Cancer Study Group. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 2004;171:1835-8.
41. Mandelbaum I, Yaw PB, Einhorn LH, Williams SD, Rowland RG, Donohue JP. The importance of one-stage median sternotomy and retroperitoneal node dissection in disseminated testicular cancer. Ann Thorac Surg 1983;36:524-8.
42. Liu D, Abolhoda A, Burt ME, et al. Pulmonary metastasectomy for testicular germ cell tumors: a 28-year experience. Ann Thorac Surg 1998;66:1709-14.
43. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Thoracotomy for postchemotherapy resection of pulmonary residual tumor mass in patients with nonseminomatous testicular germ cell tumors: aggressive surgical resection is justified. Chest 1997;112:967-73.
44. Horvath LG, McCaughan BC, Stockle M, Boyer MJ. Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Intern Med J 2002;32:79-83.
45. Kesler KA. Surgical techniques for testicular nonseminomatous germ cell tumors metastatic to the mediastinum. Chest Surg Clin N Am 2002;12:749-68.
46. Rivoire M, Elias D, De Cian F, Kaemmerlen P, Theodore C, Droz JP. Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer 2001;92:578-87.
47. Hartmann JT, Rick O, Oechsle K, et al. Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. Ann Surg 2005;242:260-6.
48. Hahn TL, Jacobson L, Einhorn LH, Foster R, Goulet RJ Jr. Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol 1999;6:640-4.
49. Bokemeyer C, Nowak P, Haupt A, et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 1997;15:1449-54.
50. Fossa SD, Bokemeyer C, Gerl A, et al. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 1999;85:988-97.
51. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems indifferential diagnosis, newly appreciated, and controversial issues. Mod Pathol 2005;18:S61-79.
52. Mostofi FK, Davis J Jr, Rehm S. Tumours of the testis. IARC Sci Publ 1994;111:407-29.